Structure Therapeutics Inc. Sponsored ADR (GPCR)
(Delayed Data from NSDQ)
$23.58 USD
+0.35 (1.51%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $26.00 +2.42 (10.26%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth C Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Structure Therapeutics Inc. Sponsored ADR's return on equity, or ROE, is -21.31% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.95%. While this shows that GPCR has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
GPCR 23.58 +0.35(1.51%)
Will GPCR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GPCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GPCR
LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
GPCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for October 23rd
Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect?
Other News for GPCR
Crossed Above 200 Day Moving Average appears for GPCR after 7.3% move
Structure Therapeutics (GPCR) Shares Cross Above 200 DMA
New Uptrend appears for GPCR after 0.64% move
Promising Market Potential for Structure Therapeutics: Buy Rating Backed by Superior Trial Results and Market Opportunities
Cantor Fitzgerald Sticks to Its Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)